Biden-era law, not Trump, drives 2026 drop in brand-drug list prices
List prices for brand-name drugs fell sharply in 2026, marking a notable decline from previous years.
Industry experts attribute the reduction primarily to a law enacted during the Biden administration that introduced new pricing disclosures and gave Medicare greater negotiating power.
President Trump has publicly claimed credit for the lower prices, but analysts say the policy changes driving the decline were implemented before his recent initiatives.
The discussion highlights how legislative actions, rather than executive rhetoric, are influencing drug pricing trends for the pharmaceutical sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that